One dose of Xyalba™ provides:

- Potency active against Gram-positive pathogens, including multi-resistant strains.
- Effective treatment for patients with comorbidities (e.g. elderly, obese, diabetic or vulnerable patients).

With:

- No dose adjustments, except for severe renal impairment.
- No monitoring of TDM (Therapeutic Drug Monitoring), blood cell, or CPK (creatinine phosphokinase).
- Low potential for drug-interactions.
- No weight-based dosing.

1 dose of Xyalba™ gives your patients
2 weeks of effective treatment in a single
30-minute infusion

= Less days in hospital.
One dose offers ...

- Ease-of-use¹
- More time and resources for you¹,²,³
- Less risk of nosocomial infections⁵
- Less days in hospital for your patients¹,²,³

Two weeks of treatment ...

- Fast (2-3 days) and long-lasting efficacy¹,²,⁴
- Fewer adverse events than comparators²,⁵,⁶
- Less concern about compliance⁷
- Less catheter related risks⁷

In a 30-minute infusion.

- More patient satisfaction⁸
- Patients experience few constraints on their daily activities⁸
- Improved convenience for you¹,²,³

¹Vancomycin/linezolid in Discover studies. ²Pooled analysis of dalbavancin-treated patients in phase 2/3 studies vs. those receiving comparator agents (vancomycin, linezolid, cefazolin, nafcillin, or oxacillin).